Experimental Drug Shows Promise in Melanoma

This article originally appeared here.
Share this content:
Experimental Drug Shows Promise in Melanoma
Experimental Drug Shows Promise in Melanoma

FRIDAY, Sept. 9, 2016 (HealthDay News) -- Pevonedistat, a specific inhibitor of the NEDD8 activating enzyme, inhibits the activity of cullin E3 ligases, inhibiting cancer cells in vitro, according to a study published in the August issue of EBioMedicine.

Noting that the cullin-based CRL4-CDT2 ubiquitin ligase regulates cell proliferation, and that CDT2 is overexpressed in cutaneous melanoma and predicts poor survival, Mouadh Benamar, from the University of Virginia in Charlottesville, and colleagues examined the role of pevonedistat in cutaneous melanoma.

The researchers found that pevonedistat inhibited activity of cullin E3 ligases, resulting in cancer cell inhibition in vitro and suppression of tumor in nude mice. Pevonedistat was effective for inhibiting proliferation of melanoma cell lines in vitro via induction of rereplication-dependent permanent growth arrest and through a transient mechanism not dependent on rereplication. Heterozygous deletion of CDKN1A (encoding p21) or SET8 in melanoma cells showed that rereplication-mediated cytotoxicity of pevonedistat was mediated via prevention of the degradation of p21 and SET8 and was necessary for suppression of melanoma in nude mice. Pevonedistat-induced transient growth suppression was independent of p21 or SET8, and was not sufficient for inhibition of in vitro tumor growth. Pevonedistat also synergized with PLX4720 to inhibit BRAF melanoma, and suppressed PLX4720-resistant melanoma cells.

"These findings demonstrate that the CRL4-CDT2-SET8/p21 degradation axis is the primary target of inhibition by pevonedistat in melanoma and suggest that a broad patient population may benefit from pevonedistat therapy," the authors write.

The authors have filed two patent applications related to this work.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Basivertebral Nerve Ablation Beneficial for Chronic Back Pain

Basivertebral Nerve Ablation Beneficial for Chronic Back Pain

Improvement in self-reported outcomes at three months in patients with chronic lumbar back pain

FDA Approves Trulance for Chronic Idiopathic Constipation

FDA Approves Trulance for Chronic Idiopathic Constipation

Drug designed to stimulate secretion of intestinal fluid

ECG Could Be Used As Password for E-Health Record Access

ECG Could Be Used As Password for E-Health ...

Researchers say heartbeat could serve as a secure 'password' for patient's electronic medical history

is free, fast, and customized just for you!

Already a member?

Sign In Now »